Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011699 | 0.98 | P4HTM (0.59) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL31474570 | 0.98 | P4HTM (0.59) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL2268319 | 0.98 | P4HTM (0.59) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| Hydrochloric Acid SCHEMBL11192074 | 0.98 | P4HTM (0.59) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL9317975 | 0.91 | P4HTM (0.54) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL9317978 | 0.90 | KDM4E (0.53) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL11411697 | 0.89 | P4HTM (0.58) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL17006990 | 0.87 | P4HTM (0.53) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL14167412 | 0.85 | KDM4E (0.54) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL2187078 | 0.84 | DRD3 (0.47) | P4HTMKDM4EL3MBTL1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116347906-A | Perovskite solar cell modified by ultrathin P-type semiconductor interface | 河北工业大学 | 2023-06-27 | — | — | CN | claimed |
| CN-112979672-B | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2022-03-11 | — | — | CN | claimed |
| CN-112979672-A | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2021-06-18 | — | — | CN | claimed |
| EP-2511268-B1 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2016-07-13 | — | — | EP | claimed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | claimed |
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | P4HTM 1357/4885KDM4E 2102/4885L3MBTL1 4206/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | P4HTM 257/4885KDM4E 1203/4885L3MBTL1 1460/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | P4HTM 1546/4885KDM4E 3548/4885L3MBTL1 4514/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | P4HTM 296/4885KDM4E 935/4885L3MBTL1 2004/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | P4HTM 1357/4885KDM4E 2102/4885L3MBTL1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.